I don't follow this one, so I am not able to even offer an inexpert opinion. The postponed committee meeting is coming up soon:
>>ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE
DATE AND TIME: January 13, 14, and 15, 8:00 a.m.
LOCATION: Holiday Inn, Versailles Ballrooms, 8120 Wisconsin Ave., Bethesda, MD.
CONTACT: Karen M. Templeton-Somers, Center for Drug Evaluation and Research, 301-827-7001. On January 13, the committee will discuss the safety and efficacy of biologic licensing application BL 103979, FABRAZYME (agalsidase beta, Genzyme Corp.) for treatment of Fabry’s disease. On January 14, the committee will discuss the safety and efficacy of biologic licensing application BL 103977, REPLAGAL (agalsidase alfa, Transkaryotic Therapies, Inc.) for the treatment of Fabry’s disease. On January 15, the committee will discuss the safety and efficacy of biologic licensing application BL 125058, ALDURAZYME (laronidase, BioMarin Pharmaceutical, Inc.) for the treatment of mucopolysaccharidosis.<<
Is there any difference between alfa and beta? One cheaper to manufacture or otherwise less costly than the other?
Reasonable questions to ask. Know nothing about the rest of their products and pipeline.
Cheers, Tuck |
